1. Home
  2. NVNI vs CELU Comparison

NVNI vs CELU Comparison

Compare NVNI & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.94

Market Cap

32.9M

Sector

N/A

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.27

Market Cap

34.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
CELU
Founded
2019
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.9M
34.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NVNI
CELU
Price
$1.94
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
139.7K
54.7K
Earning Date
09-30-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,250,627.00
$40,578,000.00
Revenue This Year
$12.05
N/A
Revenue Next Year
$15.02
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
1491.58
N/A
52 Week Low
$1.44
$1.00
52 Week High
$75.80
$4.35

Technical Indicators

Market Signals
Indicator
NVNI
CELU
Relative Strength Index (RSI) 29.90 42.00
Support Level $1.60 $1.25
Resistance Level $3.18 $1.32
Average True Range (ATR) 0.24 0.08
MACD -0.09 0.02
Stochastic Oscillator 21.52 34.37

Price Performance

Historical Comparison
NVNI
CELU

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: